RXRA and prostate carcinoma: Previous studies confirmed that EPHX2, RXRA, LTC4S and SLC25A17 were abnormally expressed in prostate cancer tissues and affected the malignant biological behaviour of prostate cancer cells and prognosis of patients (Ali et al., 2018; Liu et al., 2021; Kushwaha et al., 2022; Xue et al., 2020).